These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 23553425)

  • 1. An integrated multiple-analyte pharmacokinetic model to characterize trastuzumab emtansine (T-DM1) clearance pathways and to evaluate reduced pharmacokinetic sampling in patients with HER2-positive metastatic breast cancer.
    Lu D; Joshi A; Wang B; Olsen S; Yi JH; Krop IE; Burris HA; Girish S
    Clin Pharmacokinet; 2013 Aug; 52(8):657-72. PubMed ID: 23553425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A mechanistic pharmacokinetic model elucidating the disposition of trastuzumab emtansine (T-DM1), an antibody-drug conjugate (ADC) for treatment of metastatic breast cancer.
    Bender B; Leipold DD; Xu K; Shen BQ; Tibbitts J; Friberg LE
    AAPS J; 2014 Sep; 16(5):994-1008. PubMed ID: 24917179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates.
    Lu D; Girish S; Gao Y; Wang B; Yi JH; Guardino E; Samant M; Cobleigh M; Rimawi M; Conte P; Jin JY
    Cancer Chemother Pharmacol; 2014 Aug; 74(2):399-410. PubMed ID: 24939213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ethnic sensitivity assessment of the antibody-drug conjugate trastuzumab emtansine (T-DM1) in patients with HER2-positive locally advanced or metastatic breast cancer.
    Li C; Wang B; Lu D; Jin JY; Gao Y; Matsunaga K; Igawa Y; Nijem I; Lu M; Strasak A; Chernyukhin N; Girish S
    Cancer Chemother Pharmacol; 2016 Sep; 78(3):547-58. PubMed ID: 27423671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I and pharmacokinetic study of trastuzumab emtansine in Japanese patients with HER2-positive metastatic breast cancer.
    Yamamoto H; Ando M; Aogi K; Iwata H; Tamura K; Yonemori K; Shimizu C; Hara F; Takabatake D; Hattori M; Asakawa T; Fujiwara Y
    Jpn J Clin Oncol; 2015 Jan; 45(1):12-8. PubMed ID: 25332421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer.
    Girish S; Gupta M; Wang B; Lu D; Krop IE; Vogel CL; Burris Iii HA; LoRusso PM; Yi JH; Saad O; Tong B; Chu YW; Holden S; Joshi A
    Cancer Chemother Pharmacol; 2012 May; 69(5):1229-40. PubMed ID: 22271209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Semi-mechanistic population pharmacokinetic model of multivalent trastuzumab emtansine in patients with metastatic breast cancer.
    Chudasama VL; Schaedeli Stark F; Harrold JM; Tibbitts J; Girish SR; Gupta M; Frey N; Mager DE
    Clin Pharmacol Ther; 2012 Oct; 92(4):520-7. PubMed ID: 22968044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of trastuzumab emtansine (T-DM1) as a single agent or in combination with pertuzumab in HER2-positive breast cancer patients with recurrent or locally advanced metastatic breast cancer.
    Lu D; Li C; Riggs M; Polhamus D; French J; Agarwal P; Chen SC; Vadhavkar S; Patre M; Strasak A; Quartino A; Jin JY; Girish S
    Cancer Chemother Pharmacol; 2019 Jul; 84(1):175-185. PubMed ID: 31102024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics and exposure-response of trastuzumab emtansine in advanced breast cancer previously treated with ≥2 HER2-targeted regimens.
    Chen SC; Quartino A; Polhamus D; Riggs M; French J; Wang X; Vadhavkar S; Smitt M; Hoersch S; Strasak A; Jin JY; Girish S; Li C
    Br J Clin Pharmacol; 2017 Dec; 83(12):2767-2777. PubMed ID: 28733983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugates.
    Erickson HK; Lewis Phillips GD; Leipold DD; Provenzano CA; Mai E; Johnson HA; Gunter B; Audette CA; Gupta M; Pinkas J; Tibbitts J
    Mol Cancer Ther; 2012 May; 11(5):1133-42. PubMed ID: 22408268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ado-trastuzumab Emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast cancer.
    Lambert JM; Chari RV
    J Med Chem; 2014 Aug; 57(16):6949-64. PubMed ID: 24967516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ado-trastuzumab emtansine: a HER2-positive targeted antibody-drug conjugate.
    Corrigan PA; Cicci TA; Auten JJ; Lowe DK
    Ann Pharmacother; 2014 Nov; 48(11):1484-93. PubMed ID: 25082874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer.
    Boyraz B; Sendur MA; Aksoy S; Babacan T; Roach EC; Kizilarslanoglu MC; Petekkaya I; Altundag K
    Curr Med Res Opin; 2013 Apr; 29(4):405-14. PubMed ID: 23402224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolution of Antibody-Drug Conjugate Tumor Disposition Model to Predict Preclinical Tumor Pharmacokinetics of Trastuzumab-Emtansine (T-DM1).
    Singh AP; Maass KF; Betts AM; Wittrup KD; Kulkarni C; King LE; Khot A; Shah DK
    AAPS J; 2016 Jul; 18(4):861-75. PubMed ID: 27029797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer.
    Krop I; Winer EP
    Clin Cancer Res; 2014 Jan; 20(1):15-20. PubMed ID: 24135146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicenter Phase II study evaluating the efficacy, safety and pharmacokinetics of trastuzumab emtansine in Japanese patients with heavily pretreated HER2-positive locally recurrent or metastatic breast cancer.
    Kashiwaba M; Ito Y; Takao S; Doihara H; Rai Y; Kanatani K; Takashima S; Masuda N
    Jpn J Clin Oncol; 2016 May; 46(5):407-14. PubMed ID: 26917603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer.
    Gupta M; Lorusso PM; Wang B; Yi JH; Burris HA; Beeram M; Modi S; Chu YW; Agresta S; Klencke B; Joshi A; Girish S
    J Clin Pharmacol; 2012 May; 52(5):691-703. PubMed ID: 21953571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer.
    LoRusso PM; Weiss D; Guardino E; Girish S; Sliwkowski MX
    Clin Cancer Res; 2011 Oct; 17(20):6437-47. PubMed ID: 22003071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetics of trastuzumab emtansine in previously treated patients with HER2-positive advanced gastric cancer (AGC).
    Chen SC; Kagedal M; Gao Y; Wang B; Harle-Yge ML; Girish S; Jin J; Li C
    Cancer Chemother Pharmacol; 2017 Dec; 80(6):1147-1159. PubMed ID: 29043411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of HER2 positive advanced breast cancer with T-DM1: A review of the literature.
    Martínez MT; Pérez-Fidalgo JA; Martín-Martorell P; Cejalvo JM; Pons V; Bermejo B; Martín M; Albanell J; Lluch A
    Crit Rev Oncol Hematol; 2016 Jan; 97():96-106. PubMed ID: 26318092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.